Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of two systematic review(s)/meta-analysis(es). ^[1-2]
• Lanadelumab 300 mg administered every 2 or 4 weeks was statistically significantly more effective in reducing the Hereditary Angioedema (HAE) attack rate compared to berotralstat (150 mg once daily and 110 mg once daily), achieving a ≥90% reduction in monthly HAE attacks at a higher rate than berotralstat.
• Lanadelumab effectively reduced the number and severity of HAE attacks, improved quality of life, and decreased disability in individuals with Type I and Type II HAE, while all drugs except avoralstat were shown to lower the incidence of HAE attacks compared to placebo.
• Both lanadelumab and C1-intravenous and subcutaneous forms (INH) were comparable in reducing the severity of breakthrough attacks and in enhancing quality of life and disability compared to placebo.
• Lanadelumab did not increase the risk of adverse events, including serious adverse events, compared with placebo, and no serious adverse events were reported at a higher rate than placebo; additionally, no deaths were reported in any of the included studies.
• Berotralstat, C1-INH (all forms), and avoralstat similarly did not show an increased rate of adverse events or serious adverse events compared with placebo, indicating a favorable safety profile for these treatments.
• The studies included participants with Type I and Type II HAE, demonstrating that lanadelumab effectively reduced the number of HAE attacks, severity of breakthrough attacks, and improved quality of life and disability; however, no studies addressed Type III HAE, limiting conclusions for this subgroup.